Business Wire

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

Share

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Michel Detheux Ph.D, as Chairman of the Board and Independent Board Member, and Mojgan Hossein-Nia as Director representative of Takeda Ventures.

“We are thrilled to welcome Michel Detheux and Mojgan Hossein-Nia to our Board of Directors. Michel and Mojgan’s expertise and outstanding track record will be invaluable to Egle as we advance our clinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer and autoimmune diseases.Their expertise in the field of oncology and their experience are instrumental for us to successfully execute on our strategic priorities,said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member.

“With the role of regulatory T cells becoming clearer in oncology and auto-immunity, I am excited to join the Board of Egle in order to help the team to move their differentiated pipeline toward a clinical proof of concept and help patients with innovative drugs targeting IL-2,” said Michel Detheux, independent chairman at Egle and CEO of iTeos Therapeutics.

I am excited to join the Board of Egle in order to help the team strategize and continue to advance their pipeline to help patients in areas of unmet needs, said Mojgan Hossein-Nia, Board Member at Egle Therapeutics.

Michel Detheux, Ph.D, Michel has held the role of Chief Executive Officer at iTeos Therapeutics since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).

Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School.

Mojgan Hossein-Nia, Ph.D., Mojgan is the Head of R&D Global Portfolio Strategy and Strategic Finance, Research and Development at Takeda. She joined the company in September 2017 and currently directs portfolio strategy and management across all therapeutic areas facilitating investment decisions and overseeing R&D governance process. Additionally, she manages enabling capabilities that support portfolio management including the center of operational performance and integrated portfolio/finance digital solutions. In previous roles, she led the R&D investor relations group and built up the R&D Partnership Office, which was created to manage the overall health of R&D’s pipeline partnerships and their integration into R&D processes.

Before joining Takeda, Mojgan worked at Novartis Pharmaceuticals, building and leading multiple global functions across R&D. Mojgan’s career spans over 30 years, comprising dedicated roles in development outsourcing, global program leadership and project management, business development & licensing, and across multiple therapeutic areas including cardiovascular, metabolism, and cell & gene therapies.

Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from University of London, UK, and a diploma in pharmaceutical medicine from University of Surrey, UK.

About Egle Therapeutics SAS (Egle)

Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies.

Find out more at www.egle-tx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912516511/en/

Contacts

contact@egle-tx.com / 0033 (0)1 86 64 08 57

contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Recognized as a Top 100 Global Innovator 202513.3.2025 04:44:00 CET | Press release

The Clarivate list ranks the organizations at the forefront of technology research and innovation worldwide. Ant Group has made the list for the fourth consecutive year, with 34,576 patent applications worldwide, 97% of which are invention patents. Ant Group has been recognized for the fourth consecutive year as one of the Top 100 Global Innovators 2025 by Clarivate, a global leader in providing transformative intelligence, identifies and ranks organizations leading the world in technology research and innovation. This recognition reaffirms Ant Group's ongoing commitment to excellence in innovation, particularly in AI and other critical digital technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312994412/en/ Clarivate recognizes Ant Group as one of the Top 100 Global Innovators 2025. (Graphic: Business Wire) Gordon Samson, President, Intellectual Property, Clarivate, said, “Being recognized as a Top 100 Global I

NetApp Prices $1.25 Billion of Senior Notes13.3.2025 03:21:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the pricing of $625 million in aggregate principal amount of its 5.50% Senior Notes due 2032 that will bear interest at 5.50% per annum and $625 million in aggregate principal amount of its 5.70% Senior Notes due 2035 that will bear interest at 5.70% per annum. The offering is expected to close, subject to the satisfaction of customary closing conditions, on March 17, 2025. NetApp intends to use a portion of the net proceeds of this offering to repay its $750 million outstanding principal amount of 1.875% Senior Notes due 2025 at maturity and the remainder of the net proceeds for general corporate purposes. Goldman Sachs & Co. LLC, J.P. Morgan, BofA Securities, Wells Fargo Securities, Citigroup, and MUFG are acting as joint book-running managers. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the senior notes or any other securities nor shall there

President of Ant International: Working With All AI Models to Drive Asia Growth for Global Merchants13.3.2025 02:00:00 CET | Press release

Douglas Feagin, President of Ant International, shared strategy and business vision for the company at CNBC Converge Singapore on March 12, 2025. Ant International: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312745446/en/ Antom Copilot applies AI to help merchants implement and orchestrate payment methods while enhancing payment success rates. (Graphic: Business Wire) Connecting Global Merchants to Digital Asia "Asia is the world's fastest growth region and the most mobile in terms of payment and financial services," Feagin commented. "Especially the young population. This is the growing part of Asia and they are increasingly digitally enabled." Today, Ant International connects 1.7 billion consumer accounts of 36 digital wallets, mainly in Asia, to 90 million merchants online and offline globally. 700 million of these accounts are from the fast-growing, mobile-native Asia region, outside of China. Starting with conne

Green Street Acquires Australian Property Journal to Expand Global Reach of Green Street News12.3.2025 20:00:00 CET | Press release

-- Global News Offering Now Covers More Than 20 Countries on 3 Continents -- Green Street, the leading provider of trusted commercial real estate intelligence and unbiased insights, has acquired Australian Property Journal – Australia’s premier publication for commercial property and residential real estate covering REITs, investment sales, and leasing transactions – to expand its global Green Street News offering. The growth of Green Street News into Australia will enable Green Street to continue its mission to empower the global commercial real estate community. “This expansion marks the latest major milestone in Green Street News' growth and Green Street's overall mission to empower the global Commercial Real Estate community. We are breaking ground not only in a new country, but on a new continent to provide the most actionable insights to ourconsumer base of high-level CRE professionals. We've assembled an incredible team of journalists with a fast-paced breaking news workflow to

Xsolla Releases Q1 2025 Report on the Future of Global Gaming and Game Development: Analysis of Metrics and Emerging Trends12.3.2025 18:00:00 CET | Press release

Key Topics Include the Global Gaming Market, Mobile Monetization Trends, Player Engagement Led by Gen Z and Gen Alpha, and Rising Investments Tools and Platforms Xsolla, a leading global video game commerce company, proudly announces the release of the Q1 2025 Edition of “The Xsolla Report: The State of Play.” This detailed report provides crucial insights, trends, and opportunities shaping the gaming landscape, empowering industry professionals to adapt and thrive in today’s rapidly changing market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311510072/en/ Graphic: Xsolla The Q1 2025 Edition focuses on the rapid growth of the global gaming market, which is expected to reach $522.5 billion in 2025 and expand at a 7.25% Compound Annual Growth Rate (CAGR), hitting $691.3 billion by 2029. The United States, poised to generate the largest revenue share for mobile games, will further solidify its position as the world’s top

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye